Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

unknown1
Enrolling by invitation1
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (50.0%)
Phase 41 (50.0%)

Trials by Status

unknown125%
enrolling_by_invitation125%
terminated125%
completed125%

Recent Activity

0 active trials
Showing 4 of 4
enrolling_by_invitationphase_4

Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome

NCT06660329
completed

JAK Inhibitors' Efficacy in Bullous Pemphigoid

NCT06561256
unknownphase_3

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

NCT05451615
terminated

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

NCT04576000

Clinical Trials (4)

Showing 4 of 4 trials
NCT06660329Phase 4

Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome

Enrolling By Invitation
NCT06561256

JAK Inhibitors' Efficacy in Bullous Pemphigoid

Completed
NCT05451615Phase 3

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Unknown
NCT04576000

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4